The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan
The aim of this study was to evaluate the antibody reaction after administration of the BNT162b2 vaccine, and to reveal the factors that affect antibody production. This prospective study was carried out in the Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, in Tokyo,...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2021-10-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/12316.pdf |
| _version_ | 1797418787177234432 |
|---|---|
| author | Toshiya Mitsunaga Yuhei Ohtaki Yutaka Seki Masakata Yoshioka Hiroshi Mori Midori Suzuka Syunsuke Mashiko Satoshi Takeda Kunihiro Mashiko |
| author_facet | Toshiya Mitsunaga Yuhei Ohtaki Yutaka Seki Masakata Yoshioka Hiroshi Mori Midori Suzuka Syunsuke Mashiko Satoshi Takeda Kunihiro Mashiko |
| author_sort | Toshiya Mitsunaga |
| collection | DOAJ |
| description | The aim of this study was to evaluate the antibody reaction after administration of the BNT162b2 vaccine, and to reveal the factors that affect antibody production. This prospective study was carried out in the Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, in Tokyo, Japan, from April 15, 2021 to June 09, 2021. All our hospital’s workers who were administered the BNT162b2 vaccine as part of a routine program were included in this study. We calculated the anti-SARS-CoV-2 spike-specific antibody titter (1) before vaccination, (2) 7 to 20 days after the first vaccination, and (3) A total of 7 to 20 days after the second vaccination. The low-antibody titer group (LABG) was defined as the group having less than 25 percentiles of antibody titer. Univariate and Multivariate logistic regression analysis were performed to ascertain the effects of factors on the likelihood of LABG. A total of 374 participants were eventually included in our study, and they were divided into 94 LABG and 280 non-LABG. All samples showed significant antibody elevation in the second antibody test, with a mean value of 3,476 U/mL. When comparing the LABG and non-LABG groups, the median age, blood sugar, and HbA1c were significantly higher in the LABG group. The rates of participants with low BMI (<18.5) and high BMI (>30) were significantly higher in the LABG group. The proportion of chronic lung disease, hypertension, diabetes, dyslipidemia, autoimmune disease, and cancer were significantly higher in the LABG group. Although there was no significant difference confirmed with respect to the exercise hours per day, the proportion of participants that did not perform outdoor exercises was significantly higher in the LABG group. The time interval between the second vaccination and the second antibody test, and between the first and the second vaccination was significantly longer in the non-LABG group. In the multivariate logistic regression analysis, older than 60 years, the past history of hypertension, HbA1c higher than 6.5%, and lack of outdoor exercises were significant suppressors of antibody responses, whereas the length of days from the first to the second vaccination longer than 25 days promoted a significant antibody response. Again, our single-center study demonstrates that older than 60 years, hypertension, HbA1c higher than 6.5%, and lack of outdoor exercises were significant suppressors of antibody responses, whereas the length of days from the first to the second vaccination longer than 25 days promoted a significant antibody response. Evidence from multi-center studies is needed to develop further vaccination strategies. |
| first_indexed | 2024-03-09T06:38:00Z |
| format | Article |
| id | doaj.art-2c255452ce4e4c7da8d937aadfb76b71 |
| institution | Directory Open Access Journal |
| issn | 2167-8359 |
| language | English |
| last_indexed | 2024-03-09T06:38:00Z |
| publishDate | 2021-10-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj.art-2c255452ce4e4c7da8d937aadfb76b712023-12-03T10:54:32ZengPeerJ Inc.PeerJ2167-83592021-10-019e1231610.7717/peerj.12316The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in JapanToshiya Mitsunaga0Yuhei Ohtaki1Yutaka Seki2Masakata Yoshioka3Hiroshi Mori4Midori Suzuka5Syunsuke Mashiko6Satoshi Takeda7Kunihiro Mashiko8Department of Emergency Medicine, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanDepartment of Emergency Medicine, Jikei University School of Medicine, Tokyo, JapanDepartment of Emergency Medicine, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanDepartment of Internal Medicine, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanDepartment of Medical Engineering, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanDepartment of Pharmacy, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanDepartment of Emergency Medicine, Jikei University School of Medicine, Tokyo, JapanDepartment of Emergency Medicine, Jikei University School of Medicine, Tokyo, JapanDepartment of Emergency Medicine, Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, Tokyo, JapanThe aim of this study was to evaluate the antibody reaction after administration of the BNT162b2 vaccine, and to reveal the factors that affect antibody production. This prospective study was carried out in the Association of EISEIKAI Medical and Healthcare Corporation Minamitama Hospital, in Tokyo, Japan, from April 15, 2021 to June 09, 2021. All our hospital’s workers who were administered the BNT162b2 vaccine as part of a routine program were included in this study. We calculated the anti-SARS-CoV-2 spike-specific antibody titter (1) before vaccination, (2) 7 to 20 days after the first vaccination, and (3) A total of 7 to 20 days after the second vaccination. The low-antibody titer group (LABG) was defined as the group having less than 25 percentiles of antibody titer. Univariate and Multivariate logistic regression analysis were performed to ascertain the effects of factors on the likelihood of LABG. A total of 374 participants were eventually included in our study, and they were divided into 94 LABG and 280 non-LABG. All samples showed significant antibody elevation in the second antibody test, with a mean value of 3,476 U/mL. When comparing the LABG and non-LABG groups, the median age, blood sugar, and HbA1c were significantly higher in the LABG group. The rates of participants with low BMI (<18.5) and high BMI (>30) were significantly higher in the LABG group. The proportion of chronic lung disease, hypertension, diabetes, dyslipidemia, autoimmune disease, and cancer were significantly higher in the LABG group. Although there was no significant difference confirmed with respect to the exercise hours per day, the proportion of participants that did not perform outdoor exercises was significantly higher in the LABG group. The time interval between the second vaccination and the second antibody test, and between the first and the second vaccination was significantly longer in the non-LABG group. In the multivariate logistic regression analysis, older than 60 years, the past history of hypertension, HbA1c higher than 6.5%, and lack of outdoor exercises were significant suppressors of antibody responses, whereas the length of days from the first to the second vaccination longer than 25 days promoted a significant antibody response. Again, our single-center study demonstrates that older than 60 years, hypertension, HbA1c higher than 6.5%, and lack of outdoor exercises were significant suppressors of antibody responses, whereas the length of days from the first to the second vaccination longer than 25 days promoted a significant antibody response. Evidence from multi-center studies is needed to develop further vaccination strategies.https://peerj.com/articles/12316.pdfCOVID-19VaccineAntibodyJapan |
| spellingShingle | Toshiya Mitsunaga Yuhei Ohtaki Yutaka Seki Masakata Yoshioka Hiroshi Mori Midori Suzuka Syunsuke Mashiko Satoshi Takeda Kunihiro Mashiko The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan PeerJ COVID-19 Vaccine Antibody Japan |
| title | The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan |
| title_full | The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan |
| title_fullStr | The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan |
| title_full_unstemmed | The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan |
| title_short | The evaluation of factors affecting antibody response after administration of the BNT162b2 vaccine: a prospective study in Japan |
| title_sort | evaluation of factors affecting antibody response after administration of the bnt162b2 vaccine a prospective study in japan |
| topic | COVID-19 Vaccine Antibody Japan |
| url | https://peerj.com/articles/12316.pdf |
| work_keys_str_mv | AT toshiyamitsunaga theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT yuheiohtaki theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT yutakaseki theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT masakatayoshioka theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT hiroshimori theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT midorisuzuka theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT syunsukemashiko theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT satoshitakeda theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT kunihiromashiko theevaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT toshiyamitsunaga evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT yuheiohtaki evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT yutakaseki evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT masakatayoshioka evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT hiroshimori evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT midorisuzuka evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT syunsukemashiko evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT satoshitakeda evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan AT kunihiromashiko evaluationoffactorsaffectingantibodyresponseafteradministrationofthebnt162b2vaccineaprospectivestudyinjapan |